ARVINAS, INC. (ARVN)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-01

Key Insights

FDA approval of VEPPANU (vepdegestrant) granted ahead of the June 5, 2026 PDUFA date, marking the first-and-only FDA-approved PROTAC protein degrader for ER+/HER2-/ESR1-mutated advanced or metastatic breast cancer, representing a significant clinical validation of Arvinas' platform technology.
Company will receive a $50 million FDA approval milestone payment from Pfizer under their July 2021 collaboration agreement, though this will be partially offset by payments owed to Yale University under their June 2024 amended license agreement.
Commercialization pathway remains on track with Arvinas and Pfizer expected to announce selection of a third-party commercialization partner, indicating active progress toward market launch and revenue generation.

Insider Trading Filed: 2026-03-19

Key Insights

Noah Berkowitz, the Chief Medical Officer of Arvinas, Inc. (ARVN), sold 6,435 shares of common stock on March 18, 2026 at an average price of $11.1004 per share.
The sale was made automatically by the company to cover tax withholding obligations in connection with the vesting and settlement of 25% of Berkowitz's restricted stock units (RSUs) granted on March 18, 2024.
This transaction does not represent a discretionary trade by the reporting person, but rather a routine stock sale to satisfy tax obligations related to equity compensation.

Current Report Filed: 2026-03-18

Key Insights

Arvinas announced positive Phase 1 data for its investigational PROTAC drug ARV-102, showing greater than 50% degradation of the LRRK2 protein in the cerebrospinal fluid of Parkinson's disease patients after 28 days of treatment.
The drug was well-tolerated, with no serious adverse events reported, and demonstrated dose-dependent brain penetration and pharmacodynamic effects.
Based on these results, Arvinas plans to continue developing ARV-102 for neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction, including initiating a Phase 1b trial in progressive supranuclear palsy in Q2 2026.

Insider Trading Filed: 2026-03-09

Key Insights

Briggs Morrison, a director of Arvinas, Inc., purchased 20,000 shares of the company's common stock on March 6, 2026 at a weighted average price of $13.4035 per share.
This insider buying activity suggests that Morrison has a positive outlook on the company's future prospects and is willing to invest his own capital in Arvinas.
The amount of shares purchased represents a meaningful transaction, indicating Morrison's confidence in the company's long-term growth potential.

Current Report Filed: 2026-02-24

Key Insights

Arvinas, Inc. announced its financial results for the fourth quarter and full year 2025, indicating the company's financial performance during this period.
The company provided a corporate update, which may include information about its business operations, product development, or other strategic initiatives.
As the filing is an 8-K, it suggests the company is reporting a material event or change in its business, which could be of interest to investors.

Current Report Filed: 2026-02-12

Key Insights

Arvinas has appointed a new President, CEO and Board Chair, indicating a change in leadership and potential strategic shift for the company.
The incoming CEO, Randy Teel, has 20 years of biopharmaceutical industry experience and has held various roles at Arvinas since 2018, providing continuity in the company's operations.
The new employment agreement for the CEO includes a base salary, performance-based bonus, and equity grants, aligning his compensation with shareholder interests.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.